Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders. The company has licensing agreements with LG Chem, Ltd; Ipsen Pharma S.A.S; Camurus; RareStone Group Ltd.; joint research collaboration with Axovia Therapeutics for developing in bardet-biedl syndrome; and LG Chem, Ltd. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts. more
Time Frame | RYTM | Sector | S&P500 |
---|---|---|---|
1-Week Return | -6.2% | -2.27% | -0.57% |
1-Month Return | -8.04% | -3.96% | 1.21% |
3-Month Return | 11.33% | -9.7% | 7.57% |
6-Month Return | 24.5% | -3.37% | 11.45% |
1-Year Return | 32.66% | 3.71% | 28.48% |
3-Year Return | 444.77% | 3.8% | 29.52% |
5-Year Return | 133.97% | 39.78% | 90.66% |
10-Year Return | 84.13% | 106.91% | 203.75% |
Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | - | 35.00K | 3.15M | 23.64M | 77.43M | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":0.05,"profit":true},{"date":"2021-12-31","value":4.07,"profit":true},{"date":"2022-12-31","value":30.53,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Cost of Revenue | 834.00K | 690.00K | 599.00K | 2.13M | 9.30M | [{"date":"2019-12-31","value":8.97,"profit":true},{"date":"2020-12-31","value":7.42,"profit":true},{"date":"2021-12-31","value":6.44,"profit":true},{"date":"2022-12-31","value":22.93,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Gross Profit | (834.00K) | (690.00K) | 2.56M | 21.50M | 68.13M | [{"date":"2019-12-31","value":-1.22,"profit":false},{"date":"2020-12-31","value":-1.01,"profit":false},{"date":"2021-12-31","value":3.75,"profit":true},{"date":"2022-12-31","value":31.57,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Gross Margin | (Infinity%) | (1971.43%) | 81.01% | 90.98% | 87.99% | [{"date":"2019-12-31","value":null,"profit":false},{"date":"2020-12-31","value":-2166.97,"profit":false},{"date":"2021-12-31","value":89.04,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":96.71,"profit":true}] |
Operating Expenses | 146.00M | 136.57M | 172.61M | 200.66M | 252.48M | [{"date":"2019-12-31","value":57.83,"profit":true},{"date":"2020-12-31","value":54.09,"profit":true},{"date":"2021-12-31","value":68.37,"profit":true},{"date":"2022-12-31","value":79.48,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Operating Income | (146.00M) | (136.57M) | (170.06M) | (179.16M) | (184.36M) | [{"date":"2019-12-31","value":-14600000000,"profit":false},{"date":"2020-12-31","value":-13657500000,"profit":false},{"date":"2021-12-31","value":-17005900000,"profit":false},{"date":"2022-12-31","value":-17915700000,"profit":false},{"date":"2023-12-31","value":-18435700000,"profit":false}] |
Total Non-Operating Income/Expense | 10.54M | 5.16M | 100.89M | (3.13M) | 1.06M | [{"date":"2019-12-31","value":10.45,"profit":true},{"date":"2020-12-31","value":5.11,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-3.11,"profit":false},{"date":"2023-12-31","value":1.05,"profit":true}] |
Pre-Tax Income | (140.73M) | (134.00M) | (69.61M) | (181.12M) | (184.11M) | [{"date":"2019-12-31","value":-14072900000,"profit":false},{"date":"2020-12-31","value":-13399600000,"profit":false},{"date":"2021-12-31","value":-6961200000,"profit":false},{"date":"2022-12-31","value":-18111900000,"profit":false},{"date":"2023-12-31","value":-18411400000,"profit":false}] |
Income Taxes | (6.11M) | (3.27M) | (1.60M) | 1.96M | 564.00K | [{"date":"2019-12-31","value":-311.16,"profit":false},{"date":"2020-12-31","value":-166.62,"profit":false},{"date":"2021-12-31","value":-81.8,"profit":false},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":28.75,"profit":true}] |
Income After Taxes | (134.62M) | (130.73M) | (68.01M) | (183.08M) | (184.68M) | [{"date":"2019-12-31","value":-13462400000,"profit":false},{"date":"2020-12-31","value":-13072700000,"profit":false},{"date":"2021-12-31","value":-6800700000,"profit":false},{"date":"2022-12-31","value":-18308100000,"profit":false},{"date":"2023-12-31","value":-18467800000,"profit":false}] |
Income From Continuous Operations | (140.73M) | (134.00M) | (69.61M) | (181.12M) | (185.54M) | [{"date":"2019-12-31","value":-14072900000,"profit":false},{"date":"2020-12-31","value":-13399600000,"profit":false},{"date":"2021-12-31","value":-6961200000,"profit":false},{"date":"2022-12-31","value":-18111900000,"profit":false},{"date":"2023-12-31","value":-18553800000,"profit":false}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Net Income | (134.62M) | (130.73M) | (68.01M) | (183.08M) | (184.68M) | [{"date":"2019-12-31","value":-13462400000,"profit":false},{"date":"2020-12-31","value":-13072700000,"profit":false},{"date":"2021-12-31","value":-6800700000,"profit":false},{"date":"2022-12-31","value":-18308100000,"profit":false},{"date":"2023-12-31","value":-18467800000,"profit":false}] |
EPS (Diluted) | (3.90) | (3.05) | (3.41) | (3.48) | (3.20) | [{"date":"2019-12-31","value":-390,"profit":false},{"date":"2020-12-31","value":-305,"profit":false},{"date":"2021-12-31","value":-341,"profit":false},{"date":"2022-12-31","value":-348,"profit":false},{"date":"2023-12-31","value":-320,"profit":false}] |
These ratios help you determine the liquidity of the company. Higher is better.
RYTM | |
---|---|
Cash Ratio | 3.06 |
Current Ratio | 3.49 |
Quick Ratio | 3.34 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
RYTM | |
---|---|
ROA (LTM) | -46.24% |
ROE (LTM) | -147.90% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
RYTM | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.97 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.03 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
RYTM | |
---|---|
Trailing PE | NM |
Forward PE | NM |
P/S (TTM) | 30.41 |
P/B | 313.18 |
Price/FCF | NM |
EV/R | 28.60 |
EV/Ebitda | NM |
Rhythm Pharmaceuticals Inc (RYTM) share price today is $55.24
Yes, Indians can buy shares of Rhythm Pharmaceuticals Inc (RYTM) on Vested. To buy Rhythm Pharmaceuticals Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in RYTM stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of Rhythm Pharmaceuticals Inc (RYTM) via the Vested app. You can start investing in Rhythm Pharmaceuticals Inc (RYTM) with a minimum investment of $1.
You can invest in shares of Rhythm Pharmaceuticals Inc (RYTM) via Vested in three simple steps:
The 52-week high price of Rhythm Pharmaceuticals Inc (RYTM) is $68.58. The 52-week low price of Rhythm Pharmaceuticals Inc (RYTM) is $35.17.
The price-to-earnings (P/E) ratio of Rhythm Pharmaceuticals Inc (RYTM) is
The price-to-book (P/B) ratio of Rhythm Pharmaceuticals Inc (RYTM) is 313.18
The dividend yield of Rhythm Pharmaceuticals Inc (RYTM) is 0.00%
The market capitalization of Rhythm Pharmaceuticals Inc (RYTM) is $3.42B
The stock symbol (or ticker) of Rhythm Pharmaceuticals Inc is RYTM